Proteomic profiling of von Hippel-Lindau syndrome and multiple endocrine neoplasia type 2 pheochromocytomas reveals different expression of chromogranin B

Endocrine-Related Cancer

Volumn 14, Issue 2, 2007, Pages 463-471

  Brouwers, Frederieke M ^a   Gläsker, Sven ^b   Nave, Amanda F ^a   Vortmeyer, Alexander O ^b   Lubensky, Irina ^b   Huang, Steven ^b   Abu Asab, Mones S ^c   Eisenhofer, Graeme ^b   Weil, Robert J ^b,d   Park, Deric M ^b   Linehan, W Marston ^c   Pacak, Karel ^a   Zhuang, Zhengping ^b  

^a EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

^b NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

^d LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CATECHOLAMINE; CHROMOGRANIN B;

ADOLESCENT; ADULT; AMINO ACID SEQUENCE; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MALE; MULTIPLE ENDOCRINE NEOPLASIA; MULTIPLE ENDOCRINE NEOPLASIA TYPE 2; PHENOTYPE; PHEOCHROMOCYTOMA; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEOMICS; SCHOOL CHILD; TWO DIMENSIONAL GEL ELECTROPHORESIS; VON HIPPEL LINDAU DISEASE; WESTERN BLOTTING;

ADOLESCENT; ADRENAL GLAND NEOPLASMS; ADULT; CATECHOLAMINES; CHILD; CHROMOGRANIN B; FEMALE; HUMANS; MALE; MIDDLE AGED; MULTIPLE ENDOCRINE NEOPLASIA TYPE 2A; PHEOCHROMOCYTOMA; PROTEIN ARRAY ANALYSIS; PROTEOMICS; VON HIPPEL-LINDAU DISEASE;

EID: 34547762713     PISSN: 13510088     EISSN: None     Source Type: Journal    
DOI: 10.1677/ERC-06-0038     Document Type: Article

References (30)

1. Aprill BS, Drake AJ III, Lasseter DH & Shakir KM 1994 Silent adrenal nodules in von Hippel-Lindau disease suggest pheochromocytoma. Annals of Internal Medicine 120 485-487.
2. Bryant J, Farmer J, Kessler LJ, Townsend RR & Nathanson KL 2003 Pheochromocytoma: the expanding genetic differential diagnosis. Journal of the National Cancer Institute 95 1196-1204.
3. Eisenhofer G, Goldstein DS, Stull R, Keiser HR, Sunderland T, Murphy DL & Kopin IJ 1986 Simultaneous liquid-chromatographic determination of 3,4-dihydroxyphenylglycol, catecholamines, and 3,4-dihydroxyphenylalanine in plasma, and their responses to inhibition of monoamine oxidase. Clinical Chemistry 32 2030-2033.
4. Eisenhofer G, Lenders JW, Linehan WM, Walther MM, Goldstein DS & Keiser HR 1999 Plasma normetanephrine and metanephrine for detecting pheochromocytoma in von Hippel-Lindau disease and multiple endocrine neoplasia type 2. New England Journal of Medicine 340 1872-1879.
5. Eisenhofer G, Walther MM, Huynh T-T, Li S-T, Bornstein SR, Vortmeyer A, Mannelli M, Goldstein DS, Linehan WM, Lenders JWM et al. 2001 Pheochromocytomas in von Hippel-Lindau syndrome and multiple endocrine neoplasia type 2 display distinct biochemical and clinical phenotypes. Journal of Clinical Endocrinology and Metabolism 86 1999-2008.
6. Eisenhofer G, Huynh TT, Pacak K, Brouwers FM, Walther MM, Linehan WM, Munson PJ, Mannelli M, Goldstein DS & Elkahloun AG 2004 Distinct gene expression profiles in norepinephrine- and epinephrine-producing hereditary and sporadic pheochromocytomas: activation of hypoxia-driven angiogenic pathways in von Hippel-Lindau syndrome. Endocrine-Related Cancer 11 897-911.
7. Furuta M, Weil RJ, Vortmeyer AO, Huang S, Lei J, Huang TN, Lee YS, Bhowmick DA, Lubensky IA, Oldfield EH et al. 2004 Protein patterns and proteins that identify subtypes of glioblastoma multiforme. Oncogene 23 6806-6814.
8. Hsiao RJ, Neumann HP, Parmer RJ, Barbosa JA & O'Connor DT 1990 Chromogranin A in familial pheochromocytoma: diagnostic screening value, prediction of tumor mass, and post-resection kinetics indicating two-compartment distribution. American Journal of Medicine 88 607-613.
9. Huang SC, Koch CA, Vortmeyer AO, Pack SD, Lichtenauer UD, Mannan P, Lubensky IA, Chrousos GP, Gagel RF, Pacak K et al. 2000 Duplication of the mutant RET allele in trisomy 10 or loss of the wild-type allele in multiple endocrine neoplasia type 2-associated pheochromocytomas. Cancer Research 60 6223-6226.
10. Huh YH, Jeon SH & Yoo SH 2003 Chromogranin B-induced secretory granule biogenesis: comparison with the similar role of chromogranin A. Journal of Biological Chemistry 278 40581-40589.
11. Huynh TT, Pacak K, Brouwers FM, Abu-Asab MS, Worrell RA, Walther MM, Elkahloun AG, Goldstein DS, Cleary S & Eisenhofer G 2005 Different expression of catecholamine transporters in phaeochromocytomas from patients with von Hippel-Lindau syndrome and multiple endocrine neoplasia type 2. European Journal of Endocrinology 153 551-563.
12. Ito Y, Fujimoto Y & Obara T 1992 The role of epinephrine, norepinephrine, and dopamine in blood pressure disturbances in patients with pheochromocytoma. World Journal of Surgery 16 759-763.
13. Kim T, Tao-Cheng JH, Eiden LE & Loh YP 2001 Chromogranin A, an "on/off" switch controlling dense-core secretory granule biogenesis. Cell 106 499-509.
14. Koch CA, Mauro D, Walther MM, Linehan WM, Vortmeyer AO, Jaffe R, Pacak K, Chrousos GP, Zhuang Z & Lubensky IA 2002 Pheochromocytoma in von Hippel-Lindau disease: distinct histopathologic phenotype compared to pheochromocytoma in multiple endocrine neoplasia type 2. Endocrine Pathology 13 17-27.
15. Lee S, Nakamura E, Yang H, Wei W, Linggi MS, Sajan MP. Farese RV, Freeman RS, Carter BD, Kaelin WG, Jr et al. 2005a Neuronal apoptosis linked to EglN3 prolyl hydroxylase and familial pheochromocytoma genes: developmental culling and cancer. Cancer Cell 8 155-167.
16. Lee YS, Vortmeyer AO, Lubensky IA, Vogel TW, Ikejiri B, Ferlicot S, Benoit G, Giraud S, Oldfield EH, Linehan WM et al. 2005b Coexpression of erythropoietin and erythropoietin receptor in von Hippel-Lindau disease-associated renal cysts and renal cell carcinoma. Clinical Cancer Research 11 1059-1064.
17. Lenders JW, Eisenhofer G, Mannelli M & Pacak K 2005 Phaeochromocytoma. Lancet 366 665-675.
18. Lloyd RV, Cano M, Rosa P, Hille A & Huttner WB 1988 Distribution of chromogranin A and secretogranin I (chromogranin B) in neuroendocrine cells and tumors. American Journal of Pathology 130 296-304.
19. Neumann HP, Bausch B, McWhinney SR, Bender BU, Gimm O, Franke G, Schipper J, Klisch J, Altehoefer C, Zerres K et al. 2002a Germ-line mutations in nonsyndromic pheochromocytoma. New England Journal of Medicine 346 1459-1466.
20. Neumann HP, Hoegerle S, Manz T, Brenner K & Iliopoulos O 2002b How many pathways to pheochromocytoma? Seminars in Nephrology 22 89-99.
21. Pomares FJ, Canas R, Rodriguez JM, Hernandez AM, Parrilla P & Tebar FJ 1998 Differences between sporadic and multiple endocrine neoplasia type 2A phaeochromocytoma. Clinical Endocrinology 48 195-200.
22. Portela-Gomes GM, Stridsberg M, Grimelius L, Falkmer UG & Falkmer S 2004 Expression of chromogranins A, B, and C (secretogranin II) in human adrenal medulla and in benign and malignant pheochromocytomas. An immunohistochemical study with region-specific antibodies. Apmis 112 663-673.
23. Riccardi VM 1981 Von Recklinghausen neurofibromatosis. New England Journal of Medicine 305 1617-1627.
24. Stridsberg M & Husebye ES 1997 Chromogranin A and chromogranin B are sensitive circulating markers for phaeochromocytoma. European Journal of Endocrinology 136 67-73.
25. Taupenot L, Harper KL & O'Connor DT 2003 The chromogranin- secretogranin family. New England Journal of Medicine 348 1134-1149.
26. Vogel TW, Brouwers FM, Lubensky IA, Vortmeyer AO, Weil RJ, Walther MM, Oldfield EH, Linehan WM, Pacak K & Zhuang Z 2005 Differential expression of erythropoietin and its receptor in von Hippel-Lindau-associated and multiple endocrine neoplasia type 2-associated pheochromocytomas. Journal of Clinical Endocrinology and Metabolism 90 3747-3751.
27. Vortmeyer AO, Frank S, Jeong SY, Yuan K, Ikejiri B, Lee YS, Bhowmick D, Lonser RR, Smith R, Rodgers G et al. 2003 Developmental arrest of angioblastic lineage initiates tumorigenesis in von Hippel-Lindau disease. Cancer Research 63 7051-7055.
28. Weiler R, Fischer-Colbrie R, Schmid KW, Feichtinger H, Bussolati G, Grimelius L, Krisch K, Kerl H, O'Connor D & Winkler H 1988 Immunological studies on the occurrence and properties of chromogranin A and B and secretogranin II in endocrine tumors. American Journal of Surgical Pathology 12 877-884.
29. Wiedenmann B, Waldherr R, Buhr H, Hille A, Rosa P & Huttner WB 1988 Identification of gastroenteropancreatic neuroendocrine cells in normal and neoplastic human tissue with antibodies against synaptophysin, chromogranin A, secretogranin I (chromogranin B), and secretogranin II. Gastroenterology 95 1364-1374.
30. Winkler H & Fischer-Colbrie R 1992 The chromogranins A and B: the first 25 years and future perspectives. Neuroscience 49 497-528.